Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In VELOUR biomarker analysis, HRs for mOS favored WT KRAS exon 2 and extended RAS, but no significant interaction was found (p=0.38) despite a trend favoring RAS WT.
“In biomarker analysis, HRs for mOS favored WT KRAS exon 2 and extended RAS, although no significant interaction was found (p = 0.38) despite a trend favoring RAS WT [35].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [35]
The citation lists haven’t been fetched yet
Cited by 39
- Authors
- Wirapati, P., Pomella, V., Vandenbosch, B., Kerr, P., Maiello, E., Jeffery Grahame, M., Curca, R.-O. D., Karthaus, M., Bridgewater, J. A., Mihailov, A. C., Kiss, I., Merino, S., McKendrick Joseph, J., Saridaki, Z., Sagaert, X. J. A., & Tejpar, S.
- Affiliations
- SIB Swiss Institute of Bioinformatics (CH)
- KU Leuven (BE)
- Almac (United Kingdom) (GB)
- Casa Sollievo della Sofferenza (IT)
- Arad County Clinical Hospital (RO)
- München Klinik Neuperlach (DE)
- University College London (GB)
- Spitalul Clinic CF Cluj-Napoca (RO)
- Hospital Universitari Sant Joan de Reus (ES)
- Universitair Ziekenhuis Leuven (BE)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 28
- Pages
- iii151-iii152
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3046986182
- Cited by
- 39
- References
- 0
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 1 · 2021: 6 · 2020: 10 · 2019: 9 · 2018: 6 · 2017: 1
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, aflibercept, FOLFIRI, RAS mutations, BRAF mutation, tumor sidedness, predictive biomarkers, overall survival, progression-free survival, response rate, KRAS exon 2, gene expression profiling, subgroup analysis, second-line therapy, anti-VEGF therapy, bevacizumab
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
